Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386858 | 0.80 | PIK3CD (0.61) | MAP4K4PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3782102 | 0.79 | PIK3CD (0.57) | MAP4K4MAPK1PIK3CAMTORPIK3CD | |
| SCHEMBL21467105 | 0.79 | JAK2 (0.46) | MAP4K4MAPK1LRRK2PIK3CAMTOR | |
| SCHEMBL17970655 | 0.79 | KDR (0.51) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL30387156 | 0.77 | PIK3CD (0.59) | MAP4K4PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL13521503 | 0.76 | MAPK1 (0.41) | MAPK1LRRK2 | |
| SCHEMBL13717931 | 0.76 | SRC (0.48) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21467053 | 0.75 | PIK3CG (0.52) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL408618 | 0.75 | PIK3CD (0.55) | MAP4K4LRRK2PIK3CAPIK3CDPIK3CB | |
| SCHEMBL30387175 | 0.75 | PIK3CD (0.55) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | MAP4K4 195/4885MAPK1 236/4885LRRK2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.